SCHEMBL2128476

SCHEMBL2128476

COc1c(C=Cc2ccc(NS(C)(=O)=O)cn2)cc(-c2cc(F)c[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.59
CRBN Q96SW2 1/20 0.36
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
KCNH2 Q12809 1/20 0.33
ACVR1 Q04771 2/20 0.32
FYN P06241 1/20 0.32
TGFBR1 P36897 1/20 0.32
MET P08581 1/20 0.32
TEAD2 Q15562 1/20 0.32
PIK3CA P42336 1/20 0.32
CYP17A1 P05093 2/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31
BRD4 O60885 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1542929 1.00 CYP3A4 (0.59) CYP3A4CRBNHTR2AHTR2CKCNH2
SCHEMBL1764337 0.91 CYP3A4 (0.60) CYP3A4CRBNACVR1FYNTGFBR1
SCHEMBL1764335 0.91 CYP3A4 (0.60) CYP3A4CRBNACVR1FYNTGFBR1
SCHEMBL1542510 0.90 CYP3A4 (0.48) CYP3A4HTR2AHTR2CKCNH2CYP17A1
SCHEMBL2745167 0.88 CYP3A4 (0.58) CYP3A4CRBNACVR1FYNTGFBR1
SCHEMBL2745165 0.88 CYP3A4 (0.58) CYP3A4CRBNACVR1FYNTGFBR1
SCHEMBL1542606 0.88 CYP3A4 (0.75) CYP3A4CRBNNR3C1PGRNR3C2
SCHEMBL1542609 0.88 CYP3A4 (0.75) CYP3A4CRBNNR3C1PGRNR3C2
SCHEMBL2127396 0.88 CYP3A4 (0.53) CYP3A4CRBN
SCHEMBL1542614 0.88 CYP3A4 (0.53) CYP3A4CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US disclosed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885CRBN 1397/4885HTR2A 2735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.